Announcements Trials
Browse Landscape

Phase

Phase 1 12Phase 2 10Phase 3 2Phase 1/2 2Phase EARLY_PHASE1 1

Status

Unknown 1Active not recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 1Advanced Breast Cancer 1

Interventions

Cyclophosphamide 171Docetaxel 164Paclitaxel 160Trastuzumab 152Capecitabine 130Tamoxifen 119Letrozole 105Epirubicin 93Doxorubicin 83Anastrozole 83exemestane 77Fulvestrant 75Carboplatin 64Fluorouracil 63Radiotherapy 61pertuzumab 59Gemcitabine 55Vinorelbine 43Goserelin 39eribulin 36130-nm albumin-bound paclitaxel 36palbociclib 32Bevacizumab 32ribociclib 30Zoledronic Acid 29Lapatinib 29Methotrexate 28Drug Therapy 28Chemotherapy, Adjuvant 28Ado-Trastuzumab Emtansine 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × entinostat × Breast × Clear all
NCT02115282 2026-05-29

Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic

National Cancer Institute (NCI)

Phase 3 Active not recruiting
608 enrolled 18 charts
Breast

Breast Neoplasms

NCT03538171 2021-07-09

Ph3 Study of Exemestane With or Without Entinostat in Chinese Patients With Hormone Receptor-Positive, Locally Advanced or Metastatic Breast Cancer

Taizhou EOC Pharma Co., Ltd.

Phase 3 Unknown
375 enrolled
Breast

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡